Table 2. Costs and Effectiveness of 3 Strategies by Vaccination Age in Base Casea.
| Strategy | Cost, $ | Incremental Cost, $ | QALYs | Incremental QALYs | ICER, $ per QALYb |
|---|---|---|---|---|---|
| Vaccination Age of 60 y | |||||
| No vaccination | 549 | NA | 12.8630 | NA | NA |
| HZ/su | 642 | 93 | 12.8661 | 0.0031 | 30 084 |
| ZVL | 696 | NA | 12.8652 | NA | Dominated |
| Vaccination Age of 70 y | |||||
| No vaccination | 388 | NA | 9.2799 | NA | NA |
| HZ/su | 520 | 131 | 9.2865 | 0.0066 | 20 038 |
| ZVL | 600 | NA | 9.2862 | NA | Dominated |
| Vaccination Age of 80 y | |||||
| No vaccination | 263 | NA | 5.8720 | NA | NA |
| HZ/su | 403 | 139 | 5.8784 | 0.0064 | 21 726 |
| ZVL | 509 | NA | 5.8781 | NA | Dominated |
Abbreviations: HZ/su, adjuvanted herpes zoster subunit vaccine; ICER, incremental cost-effectiveness ratio; NA, not applicable; QALY, quality-adjusted life-year; ZVL, live attenuated herpes zoster vaccine.
a
Costs are given in 2016 US dollars.
b
A dominated strategy means that it has a higher cost but lower QALYs than the other.